InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone604-669-7207
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date9/12/2019 (Estimated)
OptionableNot Optionable
InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions
What is InMed Pharmaceuticals' stock symbol?
InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."
When is InMed Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for InMed Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMed Pharmaceuticals.
Has InMed Pharmaceuticals been receiving favorable news coverage?
Press coverage about IN stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InMed Pharmaceuticals earned a news impact score of -2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for InMed Pharmaceuticals.
Who are some of InMed Pharmaceuticals' key competitors?
Some companies that are related to InMed Pharmaceuticals include Althea Group (AGH), Harvest One Cannabis (HVT), Auscann Group (AC8), Depomed (ASRT), Eve & Co Inc (EVE), Probiotec (PBP), Delta 9 Cannabis (NINE), Biosyent (RX), Invion (IVX), Science in Sport (SIS), MGC Pharmaceuticals (MXC), Pediapharm (MDP), MMJ Group (MMJ), SugarBud Craft Growers (SUGR) and Venture Life Group (VLG).
What other stocks do shareholders of InMed Pharmaceuticals own?
Who are InMed Pharmaceuticals' key executives?
InMed Pharmaceuticals' management team includes the folowing people:
- Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
- Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.
- Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs
- Mr. Joshua Blacher, Chief Bus. Officer (Age 46)
- Dr. Eric C. Hsu, Sr. VP of Preclinical R&D
How do I buy shares of InMed Pharmaceuticals?
Shares of IN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is InMed Pharmaceuticals' stock price today?
One share of IN stock can currently be purchased for approximately C$0.26.
How big of a company is InMed Pharmaceuticals?
What is InMed Pharmaceuticals' official website?
How can I contact InMed Pharmaceuticals?
The company can be reached via phone at 604-669-7207.
MarketBeat Community Rating for InMed Pharmaceuticals (TSE IN)
MarketBeat's community ratings are surveys of what our community members think about InMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe IN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IN will underperform the S&P 500 over the long term. You may vote once every thirty days.
